Sydney IVF™ Blastocyst Cryopreservation Kit is intended for use in assisted reproduction technologies for cryopreservation of blastocysts. Sydney IVF™ Blastocyst Thawing Kit is intended for use in assisted reproduction technologies for thawing of cryopreserved blastocysts.

Device Description

Sydney IVF™ Blastocyst Freeze/Thaw Kits are aqueous solutions provided in glass vials with silicone rubber stoppers. The Sydney IVF™ Blastocyst Freezing Kit Buffers will be available in 20 mL fill volumes, the Sydney IVF™ Blastocyst Thaw Kit Buffers will be available in 20 mL fill volumes.

AI/ML Overview

The provided text is a 510(k) Premarket Notification for the Sydney IVF™ Blastocyst Freeze/Thaw Kits. This document describes a medical device (freeze/thaw kits for blastocysts in assisted reproductive technologies), not an AI/ML powered device. Therefore, many of the requested categories in the prompt, which are specific to AI/ML device studies, are not applicable.

Here's a breakdown of the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document states: "The Sydney IVF™ Blastocyst Freeze/Thaw Kits were subjected to testing to assure satisfactory operating performance. The Sydney IVF™ Blastocyst Freeze/Thaw Kits passed the requirements of all tests." However, specific numerical acceptance criteria or detailed performance metrics are not provided in this 510(k) summary. It only states that the device "passed the requirements of all tests" and is "similar, with respect to intended use and technological characteristics, to the FDA published predicate device description." This implies the acceptance criteria were met, but the criteria themselves are not listed.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not provided in the document. The type of testing performed is mentioned, but details on sample size, data provenance (country, retrospective/prospective) are absent.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not applicable as this is a medical device (reagents/media) approval, not an AI/ML diagnostic or prognostic tool requiring expert-established ground truth for a test set.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not applicable for the same reason as point 3.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not applicable as this is not an AI/ML device involving human readers or comparative effectiveness studies with AI assistance.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This concept is not applicable as this is not an algorithm or AI system.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

This information is not applicable in the context of an AI/ML device. For a medical device like this, "ground truth" would typically refer to established laboratory or clinical standards for performance such as viability, cryosensitivity, or absence of toxicity. These specific types of ground truth are not explicitly described beyond the general statement of "satisfactory operating performance."

8. The sample size for the training set

This information is not applicable as this is not an AI/ML device requiring a training set.

9. How the ground truth for the training set was established

This information is not applicable as this is not an AI/ML device.

Summary

{0}------------------------------------------------

Sydney IVF™ Blastocyst Freeze/Thaw Kits - 510(k) Premarket Notification February 6, 2003

AUG 2 9 2003

K030441

510(k) Summary ರಿ

Submitted By:

Brenda Davis Requlatory Affairs COOK OB/GYN™ 1100 West Morgan Street Spencer, Indiana, 47460. 812-829-6500

January 31, 2001

Names of Device:

Trade Name:	Sydney IVF™ Blastocyst Freeze/Thaw Kits
Common/Usual Name:	Freeze/thaw kits
Classification Name:	Reproductive media and supplements21 CFR '884.6180 (87MQL); Class II
Predicate Device:	63 FR 48428, September 10, 1998

Device Description:

Intended Use:

The Sydney IVF™ Blastocyst Cryopreservation Kit is intended for use in assisted reproduction technologies for cryopreservation of blastocysts. The Sydney IVF™ Blastocyst Thawing Kit is intended for use in assisted reproduction technologies for thawing of cryopreserved blastocysts.

Substantial Equivalence:

The Sydney IVF™ Blastocyst Freeze/Thaw Kits are comparable with respect to intended use to the published predicate device description and meet the requirements for 510(k) substantial equivalence.

Discussion of Tests and Test Results:

The Sydney IVF™ Blastocyst Freeze/Thaw Kits were subjected to testing to assure satisfactory operating performance. The Sydney IVF™ Blastocyst Freeze/Thaw Kits passed the requirements of all tests.

Conclusions Drawn from Tests:

This device is similar, with respect to intended use and technological characteristics, to the FDA published predicate device description.

{1}------------------------------------------------

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 2 9 2003

Ms. Brenda Davis Regulatory Affairs Technical Writer Cook Ob/Gyn 1100 W. Morgan Street SPENCER IN 47460

Re: K030441 Trade/Device Name: Sydney IVFTM Blastocyst Cryopreservation Kit and Sydney IVFTM Blastocyst Thaw Kit Regulation Number: 21 CFR 884.6180 Regulation Name: Reproductive media and supplements Regulatory Class: II Product Code: 85 MQL Dated: August 14, 2003 Received: August 15, 2003

Dear Ms. Davis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

{2}------------------------------------------------

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Nancy C. Brogdon

Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

K030441 510(k) Number (if known):

Sydney IVF™ Blastocyst Cryopreservation Kit Device Name:

Sydney IVF™ Blastocyst Cryopreservation Kit is intended Indications For Use: for use in assisted reproduction technologies for cryopreservation of blastocysts.

Sydney IVF™ Blastocyst Thawing Kit Device Name:

Sydney IVF™ Blastocyst Thawing Kit is intended for use Indications For Use: in assisted reproduction technologies for thawing of cryopreserved blastocysts.

(Please DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

David R. Severson

(Division Sign-Off) Division of Reproductive, Abdom and Radiological Devices 510(k) Number

Prescription Use
(Per 21 CFR 801.109)
✓

Regulation Number and Section

§ 884.6180 Reproductive media and supplements.

(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.